K Robin Yabroff, Deborah Schrag. Show Affiliations »
Abstract
Mesh： See more » Antibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Agents/economicsAntineoplastic Agents/therapeutic useBiomarkers, Tumor/analysisBiomarkers, Tumor/geneticsCanadaCetuximabColorectal Neoplasms/drug therapyColorectal Neoplasms/economicsCost-Benefit AnalysisDrug CostsHealth Care CostsHumansMutationPatient SelectionProto-Oncogene Proteins/analysisProto-Oncogene Proteins/geneticsProto-Oncogene Proteins p21(ras)Quality-Adjusted Life YearsUnited KingdomUnited Statesras Proteins/analysisras Proteins/genetics
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsCetuximab
Year: 2009 PMID： 19666852 DOI： 10.1093/jnci/djp258
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506